Wintermark Max, Luby Marie, Bornstein Natan M, Demchuk Andrew, Fiehler Jens, Kudo Kohsuke, Lees Kennedy R, Liebeskind David S, Michel Patrik, Nogueira Raul G, Parsons Mark W, Sasaki Makoto, Wardlaw Joanna M, Wu Ona, Zhang Weiwei, Zhu Guangming, Warach Steven J
Department of Radiology, Neuroradiology, Stanford University, Palo Alto, CA, USA.
National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, USA.
Int J Stroke. 2015 Jul;10(5):759-62. doi: 10.1111/ijs.12491. Epub 2015 Apr 2.
To assess the differences across continental regions in terms of stroke imaging obtained for making acute revascularization therapy decisions, and to identify obstacles to participating in randomized trials involving multimodal imaging.
STroke Imaging Repository (STIR) and Virtual International Stroke Trials Archive (VISTA)-Imaging circulated an online survey through its website, through the websites of national professional societies from multiple countries as well as through email distribution lists from STIR and the above mentioned societies.
We received responses from 223 centers (2 from Africa, 38 from Asia, 10 from Australia, 101 from Europe, 4 from Middle East, 55 from North America, 13 from South America). In combination, the sites surveyed administered acute revascularization therapy to a total of 25,326 acute stroke patients in 2012. Seventy-three percent of these patients received intravenous (i.v.) tissue plasminogen activator (tPA), and 27%, endovascular therapy. Vascular imaging was routinely obtained in 79% (152/193) of sites for endovascular therapy decisions, and also as part of standard IV tPA treatment decisions at 46% (92/198) of sites. Modality, availability and use of acute vascular and perfusion imaging before revascularization varied substantially between geographical areas. The main obstacles to participate in randomized trials involving multimodal imaging included: mainly insufficient research support and staff (50%, 79/158) and infrequent use of multimodal imaging (27%, 43/158) .
There were significant variations among sites and geographical areas in terms of stroke imaging work-up used tomake decisions both for intravenous and endovascular revascularization. Clinical trials using advanced imaging as a selection tool for acute revascularization therapy should address the need for additional resources and technical support, and take into consideration the lack of routine use of such techniques in trial planning.
评估各大陆地区在获取用于急性血管再通治疗决策的卒中影像方面的差异,并确定参与涉及多模态影像的随机试验的障碍。
卒中影像库(STIR)和虚拟国际卒中试验档案库(VISTA)-影像通过其网站、多个国家的国家专业协会网站以及STIR和上述协会的电子邮件分发列表进行在线调查。
我们收到了来自223个中心的回复(非洲2个,亚洲38个,澳大利亚10个,欧洲101个,中东4个,北美55个,南美13个)。综合来看,2012年这些被调查的机构共为25326例急性卒中患者实施了急性血管再通治疗。这些患者中有73%接受了静脉注射组织型纤溶酶原激活剂(tPA),27%接受了血管内治疗。79%(152/193)的机构在进行血管内治疗决策时常规进行血管成像,46%(92/198)的机构在进行标准静脉tPA治疗决策时也将其作为一部分。血管再通术前急性血管和灌注成像的方式、可用性和使用在不同地理区域存在很大差异。参与涉及多模态影像的随机试验的主要障碍包括:主要是研究支持和人员不足(50%,79/158)以及多模态影像使用不频繁(27%,43/158)。
在用于静脉和血管内血管再通决策的卒中影像检查方面,各机构和地理区域存在显著差异。将先进影像作为急性血管再通治疗选择工具的临床试验应满足对额外资源和技术支持的需求,并在试验规划中考虑到此类技术缺乏常规使用的情况。